Fluorescence-guided surgery using tumour-targeted imaging agents has emerged over the past decade as a promising and effective method of intraoperative cancer detection. An impressive number of fluorescently labelled antibodies, peptides, particles and other molecules related to cancer hallmarks have been developed for the illumination of target lesions. New approaches are being implemented to translate these imaging agents into the clinic, although only a few have made it past early-phase clinical trials. For this translational process to succeed, target selection, imaging agents and their related detection systems and clinical implementation have to operate in perfect harmony to enable real-time intraoperative visualization that can benefit patients. Herein, we review key aspects of this imaging cascade and focus on imaging approaches and methods that have helped to shed new light onto the field of intraoperative fluorescence-guided cancer surgery with the singular goal of improving patient outcomes.
Tumour-targeted fluorescence-guided surgery (FGS) has emerged as a promising technique for the intraoperative visualization of solid tumours.
Different approaches can be used to make imaging agents specifically bind to or interact with a target protein associated with a cancer hallmark.
Imaging systems for clinical tumour-targeted FGS are available and provide real-time qualitative images.
Phase III studies are currently ongoing to prove patient benefit from tumour-targeted FGS.
Future camera developments focus on the quantification of fluorescence imaging by correcting for an array of optical properties.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Alam, I. S. et al. Emerging intraoperative imaging modalities to improve surgical precision. Mol. Imaging Biol. 20, 705–715 (2018).
Frangioni, J. V. Translating in vivo diagnostics into clinical reality. Nat. Biotechnol. 24, 909–913 (2006).
Vahrmeijer, A. L., Hutteman, M., van der Vorst, J. R., van de Velde, C. J. & Frangioni, J. V. Image-guided cancer surgery using near-infrared fluorescence. Nat. Rev. Clin. Oncol. 10, 507–518 (2013).
Guttmann, P., Ehrlich, P. Berliner Klinische Wochenschrift 953-956 (Springer, 1891).
Moore, G. E. et al. The clinical use of fluorescein in neurosurgery; the localization of brain tumors. J. Neurosurg. 5, 392–398 (1948).
Fox, I. J. & Wood, E. H. Indocyanine green: physical and physiologic properties. Proc. Staff. Meet. Mayo Clin. 35, 732–744 (1960).
Watts, G. Bernard Fisher. Lancet 394, 1900 (2019).
Best, S. JOAN RIBAS GISPERT Coordination chemistry Wiley–VCH, 2008, 600 pp. (paperback) ISBN-10 3-527-31802-X ISBN-13 978-3-527-31802-5.
Keereweer, S. et al. Optical image-guided cancer surgery: challenges and limitations. Clin. Cancer Res. 19, 3745–3754 (2013).
Hernot, S., van Manen, L., Debie, P., Mieog, J. S. D. & Vahrmeijer, A. L. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol. 20, e354–e367 (2019).
de Geus, S. W. et al. Selecting tumor-specific molecular targets in pancreatic adenocarcinoma: paving the way for image-guided pancreatic surgery. Mol. Imaging Biol. 18, 807–819 (2016).
van Oosten, M., Crane, L. M., Bart, J., van Leeuwen, F. W. & van Dam, G. M. Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using target selection criteria (TASC): a novel target identification tool. Transl. Oncol. 4, 71–82 (2011).
Achterberg, F. B. et al. Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery. Eur. J. Nucl. Med. Mol. Imaging 48, 332–339 (2020).
Weissleder, R., Schwaiger, M. C., Gambhir, S. S. & Hricak, H. Imaging approaches to optimize molecular therapies. Sci. Transl. Med. 8, 355ps316 (2016).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Baart, V. M. et al. EGFR and αvβ6 as promising targets for molecular imaging of cutaneous and mucosal squamous cell carcinoma of the head and neck region. Cancers 12, 1474 (2020).
de Gouw, D. et al. Identifying biomarkers in lymph node metastases of esophageal adenocarcinoma for tumor-targeted imaging. Mol. Diagn. Ther. 24, 191–200 (2020).
Boogerd, L. S. et al. Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy. OncoTargets Ther. 11, 1655–1664 (2018).
Vuijk, F. A. et al. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Sci. Rep. 10, 16211 (2020).
Tummers, W. S. et al. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget 8, 56816–56828 (2017).
Hartmans, E. et al. Potential red-flag identification of colorectal adenomas with wide-field fluorescence molecular endoscopy. Theranostics 8, 1458–1467 (2018).
Boogerd, L. S. F. et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol. Hepatol. 3, 181–191 (2018).
Achterberg, F. B. et al. Real-time surgical margin assessment using ICG-fluorescence during laparoscopic and robot-assisted resections of colorectal liver metastases. Ann. Transl. Med. 8, 1448 (2020).
Lamberts, L. E. et al. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin. Cancer Res. 23, 2730–2741 (2017).
Nagengast, W. B. et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Gut 68, 7–10 (2019).
Korb, M. L. et al. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer. J. Surg. Res. 188, 119–128 (2014).
Marston, J. C. et al. Panitumumab-IRDye800CW for fluorescence-guided surgical resection of colorectal cancer. J. Surg. Res. 239, 44–51 (2019).
Harlaar, N. J. et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol. Hepatol. 1, 283–290 (2016).
Kanazawa, S. et al. VEGF, basic-FGF, and TGF-beta in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am. J. Gastroenterol. 96, 822–828 (2001).
Derks, Y. H. W. et al. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics 9, 6824–6839 (2019).
van der Fels, C. A. M. et al. Potential receptors for targeted imaging of lymph node metastases in penile cancer. Diagnostics 10, 694 (2020).
Boonstra, M. C. et al. Stromal targets for fluorescent-guided oncologic surgery. Front. Oncol. 5, 254 (2015).
Urano, Y. et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat. Med. 15, 104–109 (2009).
Debie, P. & Hernot, S. Emerging fluorescent molecular tracers to guide intra-operative surgical decision-making. Front. Pharmacol. 10, 510 (2019).
van Leeuwen, F. W. B. et al. Trending: radioactive and fluorescent bimodal/hybrid tracers as multiplexing solutions for surgical guidance. J. Nucl. Med. 61, 13–19 (2020).
Mayer, A. T. & Gambhir, S. S. The immunoimaging toolbox. J. Nucl. Med. 59, 1174–1182 (2018).
Choi, H. S. et al. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 5, 42–47 (2010).
van Dam, G. M. et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat. Med. 17, 1315–1319 (2011).
Warram, J. M. et al. Antibody-based imaging strategies for cancer. Cancer Metastasis Rev. 33, 809–822 (2014).
Gong, H., Kovar, J. L., Cheung, L., Rosenthal, E. L. & Olive, D. M. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors. Cancer Biol. Ther. 15, 185–193 (2014).
Heath, C. H. et al. Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice. Otolaryngol. Head Neck Surg. 148, 982–990 (2013).
Miller, S. E. et al. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. J. Neurooncol. 139, 135–143 (2018).
Odenthal, J. et al. Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma. Sci. Rep. 8, 10467 (2018).
Rijpkema, M. et al. SPECT- and fluorescence image-guided surgery using a dual-labeled carcinoembryonic antigen-targeting antibody. J. Nucl. Med. 55, 1519–1524 (2014).
Debie, P. et al. Improved debulking of peritoneal tumor implants by near-infrared fluorescent nanobody image guidance in an experimental mouse model. Mol. Imaging Biol. 20, 361–367 (2018).
Gao, R. W. et al. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. Theranostics 8, 2488–2495 (2018).
Hollandsworth, H. M. et al. Anti-carcinoembryonic antigen-related cell adhesion molecule antibody for fluorescence visualization of primary colon cancer and metastases in patient-derived orthotopic xenograft mouse models. Oncotarget 11, 429–439 (2020).
Koller, M. et al. Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers. Nat. Commun. 9, 3739 (2018).
Nishio, N. et al. Optimal dosing strategy for fluorescence-guided surgery with panitumumab-IRDye800CW in head and neck cancer. Mol. Imaging Biol. 22, 156–164 (2020).
Rosenthal, E. L. et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin. Cancer Res. 21, 3658–3666 (2015).
Tummers, W. S. et al. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. HPB 21, 883–890 (2019).
Tummers, W. S. et al. Intraoperative pancreatic cancer detection using tumor-specific multimodality molecular imaging. Ann. Surg. Oncol. 25, 1880–1888 (2018).
Tummers, W. S. et al. Regulatory aspects of optical methods and exogenous targets for cancer detection. Cancer Res. 77, 2197–2206 (2017).
Fakurnejad, S. et al. Intraoperative molecular imaging for ex vivo assessment of peripheral margins in oral squamous cell carcinoma. Front. Oncol. 9, 1476 (2019).
van Keulen, S. et al. The clinical application of fluorescence-guided surgery in head and neck cancer. J. Nucl. Med. 60, 758–763 (2019).
de Valk, K. S. et al. Dose-finding study of a CEA-targeting agent, SGM-101, for intraoperative fluorescence imaging of colorectal cancer. Ann. Surg. Oncol. 28, 1832–1844 (2021).
Meijer, R. P. J. et al. Intraoperative detection of colorectal and pancreatic liver metastases using SGM-101, a fluorescent antibody targeting CEA. Eur. J. Surg. Oncol. 47, 667–673 (2021).
Schaap, D. P. et al. Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Br. J. Surg. 107, 334–337 (2020).
Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci. 29, 57–61 (2008).
Lu, G. et al. Predicting therapeutic antibody delivery into human head and neck cancers. Clin. Cancer Res. 26, 2582–2594 (2020).
Moore, L. S. et al. Characterizing the utility and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patients. J. Nucl. Med. 58, 246–251 (2017).
Debie, P. et al. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours. J. Control. Rel. 317, 34–42 (2020).
Zhang, M. et al. Near-infrared dye-labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clin. Cancer Res. 25, 188–200 (2019).
Tsai, W. K. et al. Dual-modality immunoPET/fluorescence imaging of prostate cancer with an anti-PSCA Cys-minibody. Theranostics 8, 5903–5914 (2018).
Boogerd, L. S. F. et al. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: preclinical validation. Surg. Oncol. 28, 1–8 (2019).
El-Sayed, A. et al. Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts. Theranostics 8, 4856–4869 (2018).
Bernhard, W. et al. Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments. Theranostics 9, 974–985 (2019).
Bam, R. et al. Affibody-indocyanine green based contrast agent for photoacoustic and fluorescence molecular imaging of B7-H3 expression in breast cancer. Bioconjug. Chem. 30, 1677–1689 (2019).
Tummers, W. S. et al. Development and preclinical validation of a cysteine knottin peptide targeting integrin alphavbeta6 for near-infrared fluorescent-guided surgery in pancreatic cancer. Clin. Cancer Res. 24, 1667–1676 (2018).
Kintzing, J. R. & Cochran, J. R. Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr. Opin. Chem. Biol. 34, 143–150 (2016).
de Valk, K. S. et al. First-in-human assessment of cRGD-ZW800-1, a Zwitterionic, integrin-targeted, near-infrared fluorescent peptide in colon carcinoma. Clin. Cancer Res. 26, 3990–3998 (2020).
Leptin, M. The fibronectin receptor family. Nature 321, 728 (1986).
Kitagawa, T. et al. RGD-conjugated human ferritin nanoparticles for imaging vascular inflammation and angiogenesis in experimental carotid and aortic disease. Mol. Imaging Biol. 14, 315–324 (2012).
Chen, H., Niu, G., Wu, H. & Chen, X. Clinical application of radiolabeled RGD peptides for PET imaging of integrin alphavbeta3. Theranostics 6, 78–92 (2016).
Iagaru, A. et al. 18F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology 273, 549–559 (2014).
Lee, J. Y. K. et al. Review of clinical trials in intraoperative molecular imaging during cancer surgery. J. Biomed. Opt. 24, 1–8 (2019).
Olson, M. T., Ly, Q. P. & Mohs, A. M. Fluorescence guidance in surgical oncology: challenges, opportunities, and translation. Mol. Imaging Biol. 21, 200–218 (2019).
Pogue, B. W., Rosenthal, E. L., Achilefu, S. & van Dam, G. M. Perspective review of what is needed for molecular-specific fluorescence-guided surgery. J. Biomed. Opt. 23, 1–9 (2018).
Kelemen, L. E. The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander? Int. J. Cancer 119, 243–250 (2006).
Hartmann, L. C. et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer 121, 938–942 (2007).
Kalli, K. R. et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108, 619–626 (2008).
O'Shannessy, D. J. et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 3, 414–425 (2012).
Salazar, M. D. A. & Ratnam, M. The folate receptor: What does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 26, 141–152 (2007).
Keating, J. J. et al. Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model. Cancer 123, 1051–1060 (2016).
Mahalingam, S. M. et al. Evaluation of novel tumor-targeted near-infrared probe for fluorescence-guided surgery of cancer. J. Med. Chem. 61, 9637–9646 (2018).
Srinivasarao, M., Galliford, C. V. & Low, P. S. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat. Rev. Drug Discov. 14, 203–219 (2015).
Shum, C. F. et al. Novel use of folate-targeted intraoperative fluorescence, OTL38, in robot-assisted laparoscopic partial nephrectomy: report of the first three cases. J. Endourol. Case Rep. 2, 189–197 (2016).
Hoogstins, C. E. S. et al. A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer. Clin. Cancer Res. 22, 2929–2938 (2016).
Predina, J. D. et al. Intraoperative molecular imaging combined with positron emission tomography improves surgical management of peripheral malignant pulmonary nodules. Ann. Surg. 266, 479 (2017).
Predina, J. D. et al. A phase I clinical trial of targeted intraoperative molecular imaging for pulmonary adenocarcinomas. Ann. Thorac. Surg. 105, 901–908 (2018).
Boogerd, L. S. F. et al. Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. Oncotarget 9, 791–801 (2018).
Randall, L. M., Wenham, R. M., Low, P. S., Dowdy, S. C. & Tanyi, J. L. A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. Gynecol. Oncol. 155, 63–68 (2019).
Kularatne, S. A. et al. Evaluation of novel prostate-specific membrane antigen-targeted near-infrared imaging agent for fluorescence-guided surgery of prostate cancer. Clin. Cancer Res. 25, 177–187 (2019).
Netherlands Trial Register. TrialRegister.nl https://www.trialregister.nl/trial/8552 (2020).
Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392–401 (2006).
Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3–6 (2015).
Hare, J. I. et al. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 108, 25–38 (2017).
Golombek, S. K. et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv. Drug Deliv. Rev. 130, 17–38 (2018).
Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020).
Wojtynek, N. E. & Mohs, A. M. Image-guided tumor surgery: the emerging role of nanotechnology. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 12, e1624 (2020).
Tanaka, N. et al. Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity. Nat. Biomed. Eng. 1, 796–806 (2017).
Das, S. S. et al. Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers 12, 1397 (2020).
Hu, Z., Chen, W. H., Tian, J. & Cheng, Z. NIRF nanoprobes for cancer molecular imaging: approaching clinic. Trends Mol. Med. 26, 469–482 (2020).
Anselmo, A. C. & Mitragotri, S. A review of clinical translation of inorganic nanoparticles. AAPS J. 17, 1041–1054 (2015).
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1, 10–29 (2016).
Wang, Y. et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 13, 204–212 (2014).
Benezra, M. et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121, 2768–2780 (2011).
Chen, F. et al. Cancer-targeting ultrasmall silica nanoparticles for clinical translation: physicochemical structure and biological property correlations. Chem. Mater. 29, 8766–8779 (2017).
Phillips, E. et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6, 260ra149 (2014).
Zhao, T. et al. A transistor-like pH nanoprobe for tumour detection and image-guided surgery. Nat. Biomed. Eng. 1, 0006 (2016).
Frangioni, J. V. The problem is background, not signal. Mol. Imaging 8, 303–304 (2009).
Hoogstins, C. et al. Setting standards for reporting and quantification in fluorescence-guided surgery. Mol. Imaging Biol. 21, 11–18 (2019).
Deken, M. M. et al. Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer — a randomized controlled trial. Gynecol. Oncol. 159, 672–680 (2020).
Koch, M., Symvoulidis, P. & Ntziachristos, V. Tackling standardization in fluorescence molecular imaging. Nat. Photonics 12, 505–515 (2018).
Nishio, N. et al. Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment. Head Neck 42, 59–66 (2020).
Cahill, R. A. et al. Artificial intelligence indocyanine green (ICG) perfusion for colorectal cancer intra-operative tissue classification. Br. J. Surg. 108, 5–9 (2021).
Antaris, A. L. et al. A small-molecule dye for NIR-II imaging. Nat. Mater. 15, 235–242 (2016).
Wan, H. et al. A bright organic NIR-II nanofluorophore for three-dimensional imaging into biological tissues. Nat. Commun. 9, 1171–1179 (2018).
Hu, Z. et al. First-in-human liver-tumour surgery guided by multispectral fluorescence imaging in the visible and near-infrared-I/II windows. Nat. Biomed. Eng. 4, 259–271 (2020).
Kimura, R. H. et al. Evaluation of integrin alphavbeta6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Nat. Commun. 10, 4673 (2019).
Lu, G. et al. Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates. Nat. Commun. 11, 5667 (2020).
Garland, M., Yim, J. J. & Bogyo, M. A bright future for precision medicine: advances in fluorescent chemical probe design and their clinical application. Cell Chem. Biol. 23, 122–136 (2016).
Landau, M. J., Gould, D. J. & Patel, K. M. Advances in fluorescent-image guided surgery. Ann. Transl. Med. 4, 392 (2016).
Staderini, M., Megia-Fernandez, A., Dhaliwal, K. & Bradley, M. Peptides for optical medical imaging and steps towards therapy. Bioorg. Med. Chem. 26, 2816–2826 (2018).
Yang, Z. et al. Macro-/micro-environment-sensitive chemosensing and biological imaging. Chem. Soc. Rev. 43, 4563–4601 (2014).
Mochida, A., Ogata, F., Nagaya, T., Choyke, P. L. & Kobayashi, H. Activatable fluorescent probes in fluorescence-guided surgery: Practical considerations. Bioorg. Med. Chem. 26, 925–930 (2018).
Whitley, M. J. et al. A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015. J. Clin. Oncol. 32, TPS11135 (2014).
Whitley, M. J. et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci. Transl. Med. 8, 320ra324 (2016).
Smith, B. L. et al. Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system. Breast Cancer Res. Treat. 171, 413–420 (2018).
Esfahani, S. A. et al. Optical imaging with a novel cathepsin-activatable probe for enhanced detection of colorectal cancer. Am. J. Nucl. Med. Mol. Imaging 9, 230–242 (2019).
Smith, B. L. et al. Feasibility study of a novel protease-activated fluorescent imaging system for real-time, intraoperative detection of residual breast cancer in breast conserving surgery. Ann. Surg. Oncol. 27, 1854–1861 (2020).
Liu, Y. et al. Molecular imaging and validation of margins in surgically excised nonmelanoma skin cancer specimens. J. Med. Imaging 6, 016001 (2019).
Unkart, J. T. et al. Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase 1 study. Ann. Surg. Oncol. 24, 3167–3173 (2017).
Kato, D. et al. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1, 33–38 (2005).
Blum, G., von Degenfeld, G., Merchant, M. J., Blau, H. M. & Bogyo, M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3, 668–677 (2007).
Sexton, K. B., Witte, M. D., Blum, G. & Bogyo, M. Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain. Bioorg. Med. Chem. Lett. 17, 649–653 (2007).
Ofori, L. O. et al. Design of protease activated optical contrast agents that exploit a latent lysosomotropic effect for use in fluorescence-guided surgery. ACS Chem. Biol. 10, 1977–1988 (2015).
Yim, J. J., Tholen, M., Klaassen, A., Sorger, J. & Bogyo, M. Optimization of a protease activated probe for optical surgical navigation. Mol. Pharm. 15, 750–758 (2018).
Shrivastav, M. et al. Validation of near infrared fluorescence (NIRF) probes in vivo with dual laser NIRF endoscope. PLoS One 13, e0206568 (2018).
Miampamba, M. et al. Sensitive in vivo visualization of breast cancer using ratiometric protease-activatable fluorescent imaging agent, AVB-620. Theranostics 7, 3369–3386 (2017).
Walker, E. et al. A protease-activated fluorescent probe allows rapid visualization of keratinocyte carcinoma during excision. Cancer Res. 80, 2045–2055 (2020).
Withana, N. P. et al. Labeling of active proteases in fresh-frozen tissues by topical application of quenched activity-based probes. Nat. Protoc. 11, 184–191 (2016).
Chyan, W. & Raines, R. T. Enzyme-activated fluorogenic probes for live-cell and in vivo imaging. ACS Chem. Biol. 13, 1810–1823 (2018).
Onoyama, H. et al. Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV. Sci. Rep. 6, 26399 (2016).
Mizushima, T. et al. Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase-IV. Head Neck 40, 1466–1475 (2018).
Yamamoto, K. et al. Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting dipeptidyl peptidase-IV. BMC Cancer 20, 64–69 (2020).
Kuriki, Y. et al. Establishment of molecular design strategy to obtain activatable fluorescent probes for carboxypeptidases. J. Am. Chem. Soc. 140, 1767–1773 (2018).
Lozano-Torres, B. et al. An OFF–ON two-photon fluorescent probe for tracking cell senescence in vivo. J. Am. Chem. Soc. 139, 8808–8811 (2017).
Li, H. et al. Aminopeptidase N activatable fluorescent probe for tracking metastatic cancer and image-guided surgery via in situ spraying. J. Am. Chem. Soc. 142, 6381–6389 (2020).
Xu, K. et al. High selectivity imaging of nitroreductase using a near-infrared fluorescence probe in hypoxic tumor. Chem. Commun. 49, 2554–2556 (2013).
Li, Y. et al. Ultrasensitive near-infrared fluorescence-enhanced probe for in vivo nitroreductase imaging. J. Am. Chem. Soc. 137, 6407–6416 (2015).
Jiao, J. et al. Quicker, deeper and stronger imaging: a review of tumor-targeted, near-infrared fluorescent dyes for fluorescence guided surgery in the preclinical and clinical stages. Eur. J. Pharm. Biopharm. 152, 123–143 (2020).
Singh, H. et al. A pH-responsive glycyrrhetinic-acid-modified small-molecule conjugate for NIR imaging of hepatocellular carcinoma (HCC). ChemBioChem 20, 614–620 (2018).
Gioux, S., Choi, H. S. & Frangioni, J. V. Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol. Imaging 9, 237–255 (2010).
Av, D. S., Lin, H., Henderson, E. R., Samkoe, K. S. & Pogue, B. W. Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging. J. Biomed. Opt. 21, 80901 (2016).
Gioux, S. et al. FluoSTIC: miniaturized fluorescence image-guided surgery system. J. Biomed. Opt. 17, 106014 (2012).
Sajedi, S., Sabet, H. & Choi, H. S. Intraoperative biophotonic imaging systems for image-guided interventions. Nanophotonics 8, 99–116 (2019).
Matz, G. et al. Chip-on-the-tip compact flexible endoscopic epifluorescence video-microscope for in-vivo imaging in medicine and biomedical research. Biomed. Opt. Express 8, 3329–3342 (2017).
Tummers, W. S. et al. Recommendations for reporting on emerging optical imaging agents to promote clinical approval. Theranostics 8, 5336–5347 (2018).
Singh, G., Gott, M. D., Pietzsch, H.-J. & Stephan, H. Nuclear and optical dual-labelled imaging agents. Design and challenges. Nuklearmedizin. Nucl. Med. 55, 41–50 (2016).
Sibinga Mulder, B. G. et al. A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer. Am. J. Nucl. Med. Mol. Imaging 8, 282–291 (2018).
Pogue, B. W. et al. Fluorescence-guided surgery and intervention — an AAPM emerging technology blue paper. Med. Phys. 45, 2681–2688 (2018).
Valdes, P. A., Angelo, J. P., Choi, H. S. & Gioux, S. qF-SSOP: real-time optical property corrected fluorescence imaging. Biomed. Opt. Express 8, 3597–3605 (2017).
McCulloch, P. et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet 374, 1105–1112 (2009).
van Manen, L. et al. A practical guide for the use of indocyanine green and methylene blue in fluorescence-guided abdominal surgery. J. Surg. Oncol. 118, 283–300 (2018).
Armstrong, G. et al. IntAct: intra-operative fluorescence angiography to prevent anastomotic leak in rectal cancer surgery: a randomized controlled trial. Colorectal Dis. 20, O226–O234 (2018).
Jafari, M. D. et al. The use of indocyanine green fluorescence to assess anastomotic perfusion during robotic assisted laparoscopic rectal surgery. Surg. Endosc. 27, 3003–3008 (2013).
Varela, R. et al. Outcomes of DIEP flap and fluorescent angiography: a randomized controlled clinical trial. Plast. Reconstr. Surg. 145, 1–10 (2020).
Mascagni, P. et al. New intraoperative imaging technologies: innovating the surgeon’s eye toward surgical precision. J. Surg. Oncol. 118, 265–282 (2018).
The authors would like to thank Dr J.H. van Dierendonck for his artistic contribution to this article. The authors received support from the Dutch Cancer Society (KWF; young investigator grant 11289 to R.J.S.), the Dutch Organization for Scientific Research (NWO; Veni grant 016.196.059 to J.S.D.M.) and the European Commission H2020-MSCA-ITN-2019 (project number: 857894 – CAST to A.L.V.).
The authors declare no competing interests.
Many of the topics discussed in this Review were studied and described by Dr Sanjiv S. Gambhir, one of the founders of molecular imaging, who unfortunately passed away during the preparation of this manuscript in July 2020. We thank him for his exceptional mentorship and forward-looking vision.
Peer review information
Nature Reviews Clinical Oncology thanks M. Bouvet, J. Warram and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mieog, J.S.D., Achterberg, F.B., Zlitni, A. et al. Fundamentals and developments in fluorescence-guided cancer surgery. Nat Rev Clin Oncol (2021). https://doi.org/10.1038/s41571-021-00548-3